Non-small cell cancer (NSCLC) tumor markers are signs of specific types of tumors. Doctors look for these markers to aid in the diagnosis and treatment of lung cancer. Doctors use several tests to ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

A father from Seattle, Washington was shocked and overwhelmed after strangers came together to raise more than $150k for him to go through life-saving cancer treatment.

are associated with improved long-term survival compared to wedge resection for patients with early-stage non-small cell lung cancer (NSCLC). The study analyzed outcomes for more than 32,000 stage ...

Findings were similar for lung cancer-specific survival ... randomized trial showed that sublobar resection performed as well as lobectomy for NSCLC tumors ≤2 cm. Around the same time, the ...

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan ...

Despite new paradigm-shifting treatments, lung cancer remains a deadly ... as the percentage of patients whose cancer cells die by more than 90% in the resected specimen, however the definition ...

Disrupting this power plant – with the help of a puffer fish – showed a breakthrough way to fight the tumors. Small cell lung cancer (SCLC) is a highly malignant and very aggressive type of ...

received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...